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ABSTRACT 
This study investigated the use of androgen receptor (AR) reporter gene assay data in a non-animal 
exposure-led risk assessment in which in vitro anti-androgenic activity and exposure data were put 
into context using a naturally occurring comparator substance with a history of dietary consumption.  
First, several dietary components were screened to identify which selectively interfered with AR 
signaling in vitro, using the AR CALUX
®
 test.  The IC50 values from these dose-response data 
together with measured or predicted human exposure levels were used to calculate exposure:activity 
ratios (EARs) for the dietary components and a number of other well-known anti-androgenic 
substances.  Both diindolylmethane (DIM) and resveratrol are specifically-acting dietary anti-
androgens.  The EARs for several anti-androgens were therefore expressed relative to the EAR of 
DIM, and how this ‘dietary comparator ratio’ (DCR) approach may be used to make safety decisions 
was assessed using an exposure-led case study for an anti-androgenic botanical ingredient.  This 
highlights a pragmatic approach which allows novel chemical exposures to be put into context against 
dietary exposures to natural anti-androgenic substances.  The DCR approach may have utility for 
other modes of action where appropriate comparators can be identified. 
KEYWORDS 
Androgen receptor; risk assessment, in vitro approaches; dietary comparison 
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1. INTRODUCTION  
Performing safety risk assessments that are based on perturbations in cellular signaling pathways 
rather than adverse effects in animal studies requires the use of multiple tools and approaches 
(Krewski et al., 2010).  Ensuring risk assessments are protective for all relevant health effects means 
that pathways associated with cellular stress responses as well as with specific targets such as nuclear 
receptors need to be considered (Middleton et al., 2017).  A Molecular Initiating Event (MIE), is the 
initial interaction between a molecule and a biomolecule or biosystem that can be causally linked to 
an outcome via a pathway (Allen et al., 2014).  Reporter gene assays are useful tools in discovering or 
confirming the MIEs that may be associated with a specific chemical exposure, and therefore have an 
important role in the development of human-relevant mechanistic toxicological risk assessments.  One 
example of a receptor-mediated MIE is androgen receptor (AR) antagonism.  We have previously 
described how a non-animal risk assessment for anti-androgenic effects could be developed and the 
central importance of the AR to this strategy (Dent et al., 2015). 
A number of tools are already available to characterize the effects of chemical exposure on many of 
the MIEs relevant for perturbation of the hypothalamus-pituitary-testicular (HPT) axis, including AR 
(ant)agonism.  However, not all the tools needed to make the link between in vitro anti-androgenic 
activity and an adverse health effect in humans are available.  These include higher tier in vitro tools 
able to distinguish endocrine activity from adversity and computational models describing the human 
HPT axis.  Such higher tier tools may not be necessary where there is a low probability of exposure 
and effect concentrations overlapping.  This principle has already been employed to compare high 
throughput exposure data and bioactivity information from the ToxCast program (Wetmore et al., 
2015), and such in vitro to in vivo extrapolation approaches are considered robust enough to be used 
for testing prioritization (Wambaugh et al., 2018).  Comparison of AC50 or IC50 values from human-
relevant in vitro assays with human plasma exposures is therefore gaining popularity as a method of 
performing mechanistic human safety risk assessments.  In addition to broad screening using multiple 
in vitro assays representing different modes of action, this approach has also been used specifically 
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for endocrine activity using data for estrogen receptor agonism and androgen receptor antagonism 
(Dancik et al., 2015).  One question facing toxicologists performing risk assessments based on new 
approaches is whether extrapolating from in vitro AC50 or IC50 values is protective of human health, 
and what ‘margin of exposure’ is sufficient between the in vitro point of departure and the predicted 
or measured plasma exposure level to assure human safety?  One way to address these questions is to 
put margins of exposure derived from in vitro only risk assessments into context against margins of 
exposure for comparator substances with the same mode of action.  One method that has been 
proposed for estrogen agonists is to calculate the exposure:activity ratios (EARs) for test substances, 
and directly compare these with the EAR of a comparator with a history of dietary exposure (Becker 
et al., 2014; Becker et al., 2015).  In that approach for estrogen agonists, the phytoestrogen genistein 
was selected as the comparator.  An EAR for genistein was calculated by dividing the human plasma 
concentration of genistein at steady state following (determined from several studies examining 
plasma exposure following consumption of soy products) by a measure of in vitro activity for the 
estrogen signaling pathway.  Based on the assumption that normal dietary exposure to phytoestrogens 
is low risk, the EARs for genistein were then compared with EARs calculated for other estrogen 
agonists to provide ‘relative estrogenic activity exposure quotients’.  Such an approach shows promise 
because it considers exposure alongside bioactivity data, and because it is focusses on the assessment 
of human safety risk rather than an attempt to replicate the results of rodent toxicology studies 
(Krewski et al., 2010; Dent et al., 2018).  We therefore applied similar techniques to investigate the 
utility of this approach for anti-androgenic materials.  To provide the measure of anti-androgenic 
activity we selected the AR CALUX® assay (Sonneveld et al., 2005) as a human relevant and highly 
specific reporter gene assay for AR agonists and antagonists (van der Burg et al., 2010). 
The objectives of this work were to: 
- Test a number of dietary components in the AR CALUX® assay to identify a comparator that 
could be used to help put the exposure and activity of anti-androgens into context 
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- Estimate plasma exposures in humans to the dietary comparator to allow EARs for other anti-
androgens to be put into context 
- Use a case study to investigate whether this approach could be used to arrive at a safety 
decision for perturbations in AR signaling for an ingredient in a consumer product without the 
need to generate animal data.   
 
2. MATERIALS AND METHODS: AR CALUX
®
 ASSAY 
2.1. Test and reference substances 
Common dietary constituents tested in the AR CALUX
®
 assay were genistein, resveratrol, 
diindolylmethane (DIM), quercetin, and rutin.  Case study ingredients were andrographolide (AG) and 
bakuchiol.  Reference substances were dihydrotestosterone (DHT), flutamide, and 2-
hydroxyflutamide.  All test or reference substances were obtained from Sigma, with the exception of 
DHT which was either prepared as a concentration series in DMSO by Bio Detection Systems B.V. 
(BDS, Amsterdam, The Netherlands) using DHT supplied by Steraloids Inc. (purity >98%) or 
supplied by Sigma (purity ≥99%) and prepared as a concentration series in DMSO in-house.  The 
purity of all test substances was ≥95%. 
2.2. Cell culture 
AR CALUX
®
 cells were obtained and used under licence from BDS.  The cells were cultured in 
growth medium comprised of Dulbecco’s Modified Eagle Medium (DMEM/F12, Thermofisher 
31331028) containing 7.5% heat inactivated fetal calf serum (FCS), 1% non-essential amino acid 
solution (NEAA, Sigma), and 10,000U/ml penicillin/10,000 µg/ml streptomycin (Sigma).  During 
subculture, once per week 200 µg/ml G418 (gentamycin, Sigma) solution was added to the medium.  
The assay was performed in Phenol Red-free DMEM/F12 medium (Thermofisher 21041025) 
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containing 5% charcoal stripped FCS (Gibco), 1% NEAA, and 10,000U/ml Penicillin/10,000 µg/ml 
streptomycin. 
2.3. AR CALUX
®
 assay method 
The assay was conducted in a GLP compliant laboratory using test methods based on previously-
reported procedures (Sonneveld et al., 2005).  On Day 1 of the assay, cells were seeded in white, 
clear-bottomed 96-well plates at a density of 1×10
5
 cells/ml in assay medium, 100 µl of cell 
suspension per well.  Plates were incubated for at least 16-hours (37°C 5% CO2).  On Day 2, wells 
were checked to ensure 50-90% confluency.  Medium was removed and 200 µl of the test substance 
or reference standard in assay medium was added to triplicate wells.  All test/reference substances 
were tested in both the agonism and antagonism assay, with the exception of flutamide and 2-
hydroxyflutamide which were only tested in the antagonism assay.  In the agonism assay, each plate 
included a DHT concentration series (1×10
-12
 to 1×10
-7
 M) for quality control purposes as well as the 
concentration range of the test substance.  The concentration range for each test substance was 
determined by performing a cytotoxicity evaluation to ensure that the highest concentration tested did 
not cause any changes in cell number or morphology, and descending concentrations were set at half 
log intervals or closer if required to investigate a steep dose response.  Cell number was assessed 
using the Sigma Cell Counting Kit 8, and morphology was evaluated by light microscopy.  For the 
antagonism assay, the medium was supplemented with a non-saturating level of DHT approximating 
to the EC50 of this ligand (3×10
-10 M). Each plate included a flutamide concentration series (1×10-9 to 
1×10
-5
 M) for quality control purposes as well as the concentration range of the test substance.  Plates 
were incubated for 24-hours.  On Day 3, the luciferase assay was performed, using the ONE-Glo™ 
Luciferase Assay System (Promega).  Luminescence was measured in a Tecan Safire plate reader.  In 
cases where antagonism was observed (determined as at least a 20% decrease in relative induction of 
the test substance at a non-cytotoxic concentration) a specificity control assay was performed to 
ensure the decrease in relative induction was not due to a non-specific effect on e.g. general cellular 
health.  This was done by assessing whether the decrease in relative induction was reversible in a 
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saturating concentration of the ligand (DHT).  Therefore, in the specificity control assay each plate 
included the concentration range of the test substance in medium containing the non-saturating level 
of DHT, the concentration range of the test substance in a saturating level of DHT (3×10
-8
 M), which 
approximates to the EC50 × 100.  A single concentration of flutamide (1×10
-5 M) in medium 
containing each level of DHT was also included to serve as a reference.  Each experiment comprised 
at least 3 independent replicates. 
2.4. Data interpretation 
Correction for background luminescence was performed by subtracting the relative luminescence of 
the control (DMSO only) wells for each plate. The results were expressed relative to the reference 
standard, which was DHT for the agonism assay (luciferase expression at highest DHT concentration 
=100%) and Flutamide for the antagonism assay (luciferase expression at highest Flutamide 
concentration = 0%).  Data were analysed using GraphPad Prism and plotted as mean values ± SEM.  
Dose response modelling was performed on log transformed data using the non-linear variable slope 
(four parameters) equation (four-parameter logistic curve) in GraphPad for either stimulation 
(agonism assay) or inhibition (antagonism assay) according to the equation: Y=Bottom (of dose-
response curve) + (Top (of dose response curve)-Bottom)/(1+10^((LogIC50-X)×HillSlope)) using a 
least squares (ordinary) fit with a maximum of 1000 iterations.  
The antagonism assay was considered negative when there was <20% inhibition (relative induction 
≥80%) at all doses, which was a cut-off suggested by the assay vendor and used to interpret ERα 
CALUX data (OECD 2016) .  Where the antagonism assay showed inhibition of at least 20% (relative 
induction ≤80%) the specificity control assay described above was performed for all test substances 
with the exception of hydroxyflutamide, which is a well-known specifically acting anti-androgen.  For 
specifically-acting anti-androgens there is a clear right shift in the dose-response between the non-
saturating and the saturating concentration of DHT (see flutamide curves in Figure 2).  Where this 
right shift was observed, or where the test substance no longer showed an inhibition of luciferase 
induction at the saturating concentration, this provided evidence that the decrease in relative induction 
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at the non-saturating concentration was reversible and test substance was considered to be a 
specifically-acting anti-androgen.  However, if the dose response remained the same the inhibition of 
luciferase was considered to be due to a non-specific effect, and the test substance was not considered 
to be a specifically-acting anti-androgen.  This was evaluated for at least 3 individual replicates. 
3. EXPOSURE:ACTIVITY PROFILING 
Exposure:activity profiling was performed using a similar approach to that proposed for estrogenic 
responses (Becker et al., 2014; Becker et al., 2015).  Firstly, a suitable comparator was identified 
from the dietary components tested in the assay as a substance which showed a specific effect on the 
AR signaling pathway.  The only dietary components that showed these characteristics were 
resveratrol and 3,3-diindolylmethane (DIM).  DIM has previously been proposed as a promising 
dietary comparator for exposure to anti-androgens (Becker et al., 2014; Becker et al., 2015), and 
because the dose-response for DIM was more typical of a AR antagonist this was selected as the 
comparator (see results). An exposure:activity ratio was therefore calculated for DIM using the 
predicted total plasma exposure and in vitro anti-androgenic activity data.  The IC50 was selected as it 
is considered the most appropriate metric to use in EAR calculations (Becker et al., 2015): 
EAR (unitless) = 
Exposure (plasma exposure in µM) 
Activity (IC50 µM) 
Because DIM exposure varies widely between individuals (Fujioka et al., 2016), to give a 
representation of this variability, EARs were calculated using PBBK (physiologically-based 
biokinetic) modelling for individuals showing high, mean and low plasma exposures.  A sub-
population of concern with regards to perturbations in AR signaling is pregnant women, due to the 
risk of serious and irreversible harm associated with blockade of AR signaling during the fetal 
masculinization programming window (Macleod et al., 2010).  We therefore modelled plasma 
exposure to females of childbearing age to provide the benchmark EAR.   
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EARs were calculated for the remaining test substances using the same equation.  Where exposure 
data allowed, EARs for the remaining test substances were also calculated to describe the variability 
in human exposures.  Where the dose-response was not sufficiently well described to confidently set 
the IC50, the concentration at which the response of the test substance equalled 50% of the maximum 
response of the reference standard (flutamide) was calculated and this value (termed the PC50) was 
used instead (OECD 2016).  EARs were also calculated using AR CALUX
®
 IC50 values found in the 
literature for the anti-androgens p,p’-DDE, vinclozolin, methoxychlor, HPTE, and BPA (Sonneveld et 
al., 2005; Suzuki et al., 2011; Wang et al., 2014) 
Dietary comparator ratios (DCRs) were calculated based on the ratio of the EAR for the test substance 
to the EAR for DIM: 
DCR = 
EARTest substance 
EARDIM 
In considering these comparisons it should be noted that some of the EARs were calculated using 
serum or plasma exposure measured in males, most notably flutamide and hydroxyflutamide.  The 
purpose of including these substances was to illustrate ‘high risk’ DCRs, encompassing exposures that 
are intended to completely suppress AR signaling in humans (in the case of flutamide and its active 
metabolite hydroxyflutamide, adult males suffering from prostate cancer).  Complete suppression of 
AR signaling following flutamide administration to pregnant rats has been shown to cause serious and 
irreversible adverse effects on their male offspring (Macleod et al., 2010).  It is therefore considered 
that the DCRs determined for flutamide and hydroxyflutamide would indicate a high probability of 
impacting AR signaling in all populations including pregnant women.  
Variability in DCR was expressed where data allowed the range of variability in human exposure to 
be characterized by calculating DCRs for the highest EARTest substance/the lowest EARDIM, the mean (or 
where appropriate median) EARTest substance/the mean EARDIM and the lowest EARTest substance/the highest 
EARDIM.  Where the range of variability was not available (e.g. for flutamide and hydroxyflutamide) 
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the variability in DCR was expressed by calculating this parameter for the mean EARTest substance/the 
lowest, mean and highest EARDIM (see supplementary materials for more detail and all calculations). 
4. EXPOSURE ASSESSMENT 
It was only necessary to perform exposure assessments for those test substances showing anti-
androgenic activity in the AR CALUX® assay, since EARs cannot be calculated for substances 
showing no activity.  The human plasma or serum exposures that were used in the EAR calculations 
were either found in the literature or generated using a PBBK model.  References used to provide the 
exposure data are summarized in Table 1, and full details of the exposure data or predictions used and 
all EAR and DCR calculations are provided in the supplementary material. 
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Table 1: Exposure data used in calculation of EARs (see supplementary materials for all exposure data and 
predictions used) 
Substance (description) Exposure data description Reference 
DIM (metabolite of 
glucobrassicin, widely 
consumed in cruciferous 
vegetables) 
PBBK model predicting DIM plasma exposure (Cmax) 
following consumption of 50 g brussels sprouts 
Reported here (see 
supplementary 
materials) 
Resveratrol (present in 
skin of berries including 
grapes) 
Human pharmacokinetic data describing Cmax following 
exposure to 25 mg resveratrol.  This represents a high level of 
dietary intake (Presta et al., 2009) but is well below the level 
used as a food supplement (Raederstorff et al., 2013). 
(Goldberg et al., 2003) 
Flutamide and 
hydroxyflutamide 
(prostate cancer drug and 
its active metabolite) 
Human pharmacokinetic data describing Cmax at steady state 
following repeated exposure therapeutic dose of flutamide 
(Radwanski et al., 
1989) 
BPA (industrial 
chemical) 
Predicted plasma concentration at steady state (Css) based on 
kinetic modelling at human exposures of 4 µg/kg/day (the 
Tolerable Daily Intake (TDI) set by European Food Safety 
Authority (EFSA)) 
(Wetmore et al., 2012) 
Vinclozolin (plant 
protection product) 
Predicted plasma Css based on kinetic modelling at human 
exposures of 25 µg/kg/day (the Reference Dose (RfD) set by 
the US Environmental Protection Agency (EPA)) 
(Wetmore et al., 2012) 
Methoxychlor (plant 
protection product) 
Predicted Css based on kinetic modelling at human exposures 
of 5 µg/kg/day (the RfD set by the US EPA) 
(Wetmore et al., 2012) 
HPTE (metabolite of 
methoxychlor) 
Predicted Css based on kinetic modelling at human exposures 
of 5 µg/kg/day (the RfD for methoxychlor set by the US EPA) 
(Wetmore et al., 2012) 
p,p’-DDE (metabolite of 
the insect control agent 
DDT) 
Human biomonitoring describing serum levels of populations 
exposed in the USA in the 1950s and 1960s and a population 
exposed in a DDT-sprayed area in South Africa in 2003-2005. 
(Longnecker et al., 
2002; Bhatia et al., 
2005; Aneck-Hahn et 
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al., 2006) 
Bakuchiol (risk 
assessment case study) 
PBBK model predicting bakuchiol plasma exposure (Cmax) 
following once-daily use of a body lotion or a shampoo 
containing this substance at 0.5% (hypothetical products) 
Reported here (see 
supplementary 
materials) 
No exposure assessment was performed for AG, which was negative in the AR CALUX
®
 assay (see Section 
5.1). 
5. RESULTS 
5.1. AR CALUX
®
 assay 
A summary of the results for AR CALUX® assays is shown in Table 2.  None of the test substances 
showed a positive response in the agonism assay, whereas in each experiment DHT gave a consistent 
positive response with very little variability between experimental replicates. 
As expected, flutamide was less potent in the antagonism assay than was its active metabolite 2-
hydroxyflutamide (Table 2, Figure 1). 
Quercetin, rutin and AG gave negative results in the antagonism assay, since in all 3 replicates there 
was less than a 20% reduction in relative luciferase induction at any concentration.  Flutamide (which 
was run on all plates) showed the expected antagonistic response. 
Genistein met the criteria to progress to a specificity control assay (20% reduction in relative 
induction).  A specificity control assay was therefore performed to ensure this was due to a specific 
effect on the AR signaling pathway, which showed the reduction in relative induction of luciferase for 
flutamide was reversible in the presence of a saturating concentration of DHT for all 3 replicates 
(Figure 2).  However, for genistein the dose response showed no right shift in the presence of a 
saturating concentration of DHT.  This indicates that the reduced luciferase expression was due to an 
effect unrelated to the AR signaling pathway, and genistein was not acting as a specific AR antagonist 
in this assay, and highlights the value of the specificity control assay. 
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Resveratrol showed a clear reduction in relative induction, and the dose-response was so steep that 
additional experiments were performed to ensure the full dose -response could be described (Figure 
2).   The steep dose-response curve for resveratrol did complicate data interpretation, but overall the 
data indicated that the effect on relative induction was considered at least partly reversible with a 
slight increase in IC50 from 2.17×10
-5 to 2.73×10-5 M. 
DIM showed a clear reduction in relative luciferase induction, meeting the criteria for specificity 
control testing.  Addition of the saturating concentration of DHT clearly shifted the dose-response to 
the right (Figure 2), increasing the IC50 from 1.27×10
-6
 to 7.50×10
-6
 M, indicating the effect on 
luciferase expression was reversible and that DIM was acting as a potent and specific AR antagonist.  
DIM was therefore selected as the dietary comparator, primarily because the dose response was more 
clearly typical of an AR antagonist than was the dose response for resveratrol.  In addition, although 
some studies have shown a health protective effect of either resveratrol or red wine (Baur and Sinclair 
2006), the safety of liberal consumption of crucifers is less contentious than consumption of red wine.  
The assumption is that although DIM is a potent anti-androgen, normal dietary consumption of 
cruciferous vegetables is not expected to cause adverse effects in humans relating to disturbance of 
AR signaling. 
Bakuchiol showed a clear dose-dependent reduction in relative luciferase induction (Figure 2), with 
the 2 highest concentrations resulting in >20% reduction.  GraphPad was unable to make a full dose-
response fit to the bakuchiol data, meaning a reliable IC50 for bakuchiol could not be calculated.  
Additional (higher) concentrations of bakuchiol would be necessary to fully describe the dose-
response, but since the highest concentration of 3 µM was close to the cytotoxic dose range a higher 
dose was not tested, and instead a mean PC50 value across all 6 replicates was calculated (Table 2).  
The relationship between the relative induction values of bakuchiol at the non-saturating 
concentration of the ligand (DHT) with the saturating concentration confirmed that addition of the 
saturating concentration reversed the effect on luciferase induction in all 6 replicates (Figure 2).  
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Therefore, the specificity control assay did indicate that the reduction in relative luciferase induction 
was a specific effect on AR-mediated signaling. 
Table 2: AR CALUX
®
 assay results 
Substance Agonism assay Antagonism assay Antagonism assay IC50 
 positive or negative (+/-) (µM)* 
Flutamide  NT + 0.876 
Hydroxyflutamide NT + 0.0282 
Genistein - - - 
Resveratrol - + 21.7 
Rutin hydrate - - - 
Quercetin hydrate - - - 
DIM - + 1.27 
Bakuchiol - + 2.85# 
AG - - - 
All values presented to 3 significant figures 
NT Not tested 
* Best-fit IC50 from at least 3 independent experiments at a non-saturating concentration of DHT 
# PC50 value presented as a reliable IC50 value could not be obtained from the dose-response  
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 5.2. In vitro to in vivo extrapolation 
A comparison of the in vitro points of departure (IC50 or for bakuchiol PC50) including upper and 
lower 95% CI where this could be calculated, and the in vivo exposure data or predictions are shown 
in Figure 3.  For only 2 substances were the predicted or measured systemic exposures greater than 
the in vitro points of departure: hydroxyflutamide and p,p’-DDE exposure values from one study 
(Aneck-Hahn et al., 2006).  For all other case substance exposures, the in vitro point of departure was 
greater than the predicted or measured systemic exposure. 
5.3. Dietary comparator ratios (DCRs) 
Calculations showing the individual EARs and corresponding DCRs are detailed in the supplementary 
materials, and a comparison of the resulting DCRs is shown in Figure 4.  Due to its low 
bioavailability, the mean DCR for DIM was the lowest calculated.  The DCR range for resveratrol, 
vinclozolin, BPA and methoxychlor overlapped with the DCR range for DIM.  Aside from the 
shampoo case study (see section 5.4), all other substance exposures provided DCRs that did not 
overlap with the range for DIM, with hydroxyflutamide providing the highest value, with a mean 
DCR of 594,000. 
5.4. Case study risk assessment 
Once we had determined the DCRs for the substances described above, we considered how this 
approach could be used to assist safety decision making using a hypothetical case study, the use of 
bakuchiol or AG in a body lotion or shampoo at 0.5%.  In a safety risk assessment for a real consumer 
product other MIEs and pathways would also need to be considered, but since the purpose of this case 
study was to evaluate the DCR methodology we concentrated solely on AR antagonism.   
AG was negative in both the agonism and antagonism assay and was therefore not taken forward as 
the subject of the risk assessment case study.  The positive result in the AR CALUX® (antagonism) 
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assay for bakuchiol was clear, although this substance was amongst the least potent anti-androgens 
tested (Table 2; Figure 3).  The exposure assessment based on worst-case consumer exposure to 0.5% 
bakuchiol in a body lotion or shampoo predicted plasma exposure for adult females of 0.320 and 
0.00234 µM respectively.  The in vitro point of departure (in this case the PC50) was below these 
predicted human exposure levels.  To further put this margin into context, the DCRs for bakuchiol in 
body lotion and shampoo were calculated (Figure 4).  The mean DCR for bakuchiol body lotion was 
151, which is in a similar range to the p,p’-DDE exposures included in the benchmarking.  The mean 
DCR for bakuchiol at 0.5% in shampoo was 2.34.  
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6. DISCUSSION 
Using the EAR for DIM as a comparator with other substances by calculating their dietary comparator 
ratio (DCR) is a pragmatic risk ranking approach, whereby DCRs below 1 provide strong assurance 
that adverse effects in humans relating to perturbations in AR signaling are very unlikely for that 
exposure scenario.  It is important to note that a DCR greater than 1 does not necessarily indicate high 
risk.  If that were the case consumption of anything more than 50 g brussels sprouts would be 
considered by this approach to be harmful (see supplementary material for DIM exposure modelling).  
However, the closer the DCR is to the anti-androgenic drug flutamide and its active metabolite 
hydroxyflutamide, the greater the risk.  This is because systemic exposure to hydroxyflutamide 
following therapeutic use of flutamide is intended to completely supress AR signaling, and as such 
significant health effects relating to AR signaling would be expected in any population exposed to 
these levels.  Use of DCRs for risk ranking requires careful consideration of the mode of action of the 
substance being risk assessed and how this compares with the dietary comparator. 
The range of DCRs for resveratrol, BPA, vinclozolin and methoxychlor overlapped with the range of 
DCRs for DIM.  The DCRs for the methoxychlor metabolite HPTE were outside the range of DCRs 
for DIM.  The exposure assessments for BPA, vinclozolin and methoxychlor were based on the 
assumption that the reference dose or TDI for these substances was ingested, and HPTE was based on 
the assumption that the reference dose of methoxychlor was ingested and completely converted to 
HPTE, which is clearly worst-case.  Since the reference doses or TDI for BPA, vinclozolin and 
methoxychlor were set to be protective of all adverse effects on human health (including those 
relating to AR signaling in both adults and the developing fetus) although some were >1, the DCR for 
these substances are also likely to represent a ‘region of safety’.  The exposure assessment for 
resveratrol was based on consumption of 25 mg/day.  Although some have described this as 
representing a moderate intake of red wine (Walle 2011), depending on the variety it is possible that 
well over 600 ml of red wine may need to be consumed to reach this level of intake (Presta et al., 
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2009).  The DCR approach suggests that even at this level of intake the resveratrol present in the wine 
is unlikely to have any significant AR-mediated adverse effects. 
The progression from an MIE to an adverse outcome is dependent on the magnitude and duration of 
the initial interaction, and transient activation of an MIE or a key event may not result in an adverse 
outcome.  It is therefore important to understand these dose-dependent transitions (or ‘tipping points’) 
to ensure the risk assessment is relevant to the protection of human health (Slikker et al., 2004a; 
Slikker et al., 2004b).  From our data it is not possible to accurately determine a tipping point, that, if 
reached would indicate a transition from adaptation to adversity.  When considering whether it was 
feasible to set a tipping point, we investigated whether exposures to p,p’-DDE, the active metabolite 
of the organochlorine pesticide DDT could provide some useful insights.  Exposures to DDT and p,p’-
DDE have been associated with a number of adverse health effects, including adverse 
developmental/reproductive effects relating to the AR signaling pathway such as cryptorchidism and 
hypospadias, and numerous epidemiology studies have been performed examining the link between 
serum p,p’-DDE levels and adverse outcomes (Bonde et al., 2016).  Case control studies investigating 
the relationship between exposure to p,p’-DDE and birth defects which were based on data collected 
in the USA in the 1950s and 1960s with median maternal serum levels in the control groups of 34.3 
µg/l (Longnecker et al., 2002) or 43 µg/l (Bhatia et al., 2005) have failed to show a conclusive 
association between exposure and hypospadias or cryptorchidism.  Studies performed in areas where 
DDT is still used for malarial control have shown some associations between adult (male) serum 
levels of p,p’-DDE and sperm quality/quantity.  For instance, in one cross-sectional study of 311 adult 
men from a DDT-sprayed area in South Africa with a median serum p,p’-DDE level of 697 µg/l, 
exposure was associated with impaired sperm motility, sperm cytoplasmic droplets, reduced ejaculate 
volume, and oligozoospermia (Aneck-Hahn et al., 2006).  We calculated EARs and DCRs for these 
p,p’-DDE exposure scenarios using published AR CALUX® data (Suzuki et al., 2011) to see how 
they compared, and only the exposure data from the high exposure study in South Africa (Aneck-
Hahn et al., 2006) exceeded the IC50 for p,p’-DDE.  When interpreting these data, it is important to 
remember that the case-control studies reflected maternal serum exposure, whereas the cross-sectional 
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study reflected adult male serum exposure.  Therefore, it is not appropriate to use these data to define 
a transition from ‘endocrine activity’ to ‘endocrine disruption’.  They are however informative for the 
purposes of risk ranking.  It should be noted that although most studies investigating the effects of 
lower exposures to DDT or p,p’-DDE (e.g. recent studies in developed countries) do not show any 
associations between either maternal or adult male exposure and birth defects or impaired sperm, 
some have shown an association.  For example, one well conducted study has shown an association 
between maternal serum exposures of  around 1 ng/ml and hypospadias (Rignell-Hydbom et al., 
2012).  Whether the association seen in that study was due to p,p’-DDE exposure is not clear, 
especially given the large number of studies at similar exposure levels which have not found 
associations (Carmichael et al., 2010; Giordano et al., 2010).  These include investigations into the 
potential for long-term effects of in utero exposure to p,p’-DDE.  For example, in a well-designed 
study 176 male offspring from a Danish cohort of women, there was no relationship between maternal 
p,p’-DDE levels and long term consequences on male reproductive health with median maternal 
serum levels of 8 pmol/ml (2.54 ng/ml) (Vested et al., 2014).  Given the contentious nature of 
potential low dose effects we have focussed our evaluation on populations exposed to high levels of 
p,p’-DDE.  This is in line with the conclusions of the US Agency for Toxic Substances and Disease 
Registry, which concluded that if a relationship between p,p’-DDE exposure and adverse 
reproductive/developmental outcomes in humans exists, it is found in populations exposed to high 
DDT concentrations (ATSDR 2002; ATSDR 2008). 
AG was negative in the AR CALUX
®
 assay, which was surprising given the existing in vitro and in 
vivo data.  Although several rat male fertility studies on either A. paniculata or AG have shown no 
adverse effects (Burgos et al., 1997; Allan et al., 2009), others have shown marked adverse effects on 
fertility (Akbarsha et al., 2000; Akbarsha and Murugaian, 2000; Sattayasai et al., 2010). AG is also 
reported to affect androgen signaling in prostate cancer cell lines (Liu et al., 2011), suggesting an 
ability to reduce AR expression at the transcriptional level, inhibit nuclear translocation of AR, inhibit 
the formation of stabilizing complexes with the co-chaperone Hsp90, slow the growth of C4-2 
prostate cancer cells, and induce apoptosis.  This was the reason for including AG in this evaluation.  
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The lack of response seen in our study likely reflects differences between AR CALUX® cells and C4-
2 cells, which were originally derived from LNCaP prostate cancer cells (Wu et al., 1994).  Given 
these conflicting data, logical next steps for the evaluation of AG include assessing the reproducibility 
of the findings in C4-2 cells and assessing whether metabolism of AG could account for differences 
between these cell types. 
Because different assays may provide different AC50 or IC50 values for the same test substance, it is 
important to ensure that all data used for a specific mode of action are comparable, i.e. produced in 
the same assay system, and that dose-response information from that system are reproducible.  The 
available pre-validation data on the AR CALUX
®
 assay shows that the average IC50s were within a 
factor of 3 between 2 laboratories (van der Burg et al., 2010), and in our study where the same 
substance (flutamide) was used our IC50 value was similar to the published range.  In the pre-
validation study the average IC50 values for flutamide following 6 or 7 experiments were 0.399 and 
0.516 µM for laboratory 1 and laboratory 2 respectively, and our IC50 value was 0.876 µM. 
Although the in vitro point of departure for bakuchiol (in this case the PC50) was below the predicted 
human exposure levels following use in both shampoo and body lotion, it was close for body lotion 
(approximately 10-fold below).  The DCR for bakuchiol at 0.5% in body lotion was in a similar range 
to the DCRs calculated for the p,p’-DDE exposures included in the benchmarking, and the DCR for 
bakuchiol at 0.5% in shampoo overlapped with range of DCRs for DIM.  With the current predictions, 
exposure to bakuchiol at 0.5% in a body lotion suggests the possibility that AR signaling may be 
perturbed in consumers, indicating the need for a more detailed evaluation in higher-tier models.  
Alternatively, exposure to bakuchiol at 0.5% in a shampoo appears low risk for this mode of action. 
6.1. Sources of uncertainty  
As with any risk assessment, there are several uncertainties with this approach that need to be 
understood to enable informed safety decision making.  These include the reliance on predicted 
plasma exposures for the dietary comparator DIM.  However, as described in the supplementary 
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materials, sufficient data were available to build a model which correlated well with measured human 
plasma levels following administration of a known quantity of absorption-enhanced DIM and 
confidence that these predictions are suitable for the purpose of this investigation is high.   
The skin penetration parameters used in the bakuchiol PBBK model were all predicted, and no human 
kinetic data were available to assess the performance of the model, meaning confidence in these 
predictions is much lower than confidence in the DIM model (see supplementary materials).  Further 
data generation, especially in vitro skin penetration, plasma protein binding and hepatocyte clearance 
would refine the exposure model, and obtaining human kinetic data to evaluate the performance of the 
model would greatly increase confidence in the model predictions.   
In this study plasma Cmax was used as the measure of exposure.  Some substances, like resveratrol and 
DIM are very rapidly cleared, whereas others, like p,p’-DDE are very persistent.  This is significant 
because clearance of anti-androgens is an important determinant in their efficacy (Gao et al., 2005).  
DCR values must therefore be considered alongside the overall pharmacokinetic profile of the 
substance being evaluated.  In other words, substances in the ‘region of safety’ which are much more 
persistent than DIM and the other benchmark substances may require further evaluation. 
In Figure 3 we were able to characterize the level of uncertainty or variability for some but not all 
bioactivity or exposure data.  As described in the supplementary materials, a measure of uncertainty 
or variability was available in the exposure data for all test substances apart from flutamide, 
hydroxyflutamide and resveratrol.  A measure of uncertainty or variability was presented in the 
bioactivity data we generated, since in Figure 3 the best-fit and lower and upper 95% confidence 
intervals (CI) of the IC50 were presented.  However, since there was very little variability in the data 
the error bars are generally not visible on the logarithmic scale.  The lack of 95% CI for the published 
AR CALUX
®
 data is therefore not considered to be a significant contributor to uncertainty within the 
risk assessment. 
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A number of anti-androgenic substances, including flutamide, methoxychlor and vinclozolin, have 
metabolites which are more potent than the parent.  This exposes a potential weakness in the way we 
performed the AR CALUX
®
 assay, i.e., without metabolic activation. This refinement has been 
described (Mollergues et al., 2017) and would be a useful additional test to include to provide further 
information, firstly on whether a metabolite of AG could cause transcriptional effects in the AR 
pathway, and also whether a metabolite of bakuchiol could be more active than its parent. 
The in vitro to in vivo comparisons we have performed were based on total concentration rather than 
free concentration in test media and plasma, which in general are considered a more appropriate dose 
metric for in vitro to in vivo extrapolation (Groothuis et al., 2015).  Therefore, any comparison for a 
substance that shows different kinetics in vitro and in vivo (e.g. those that are extensively bound to 
plastic or serum) will be flawed.  A lot of the substances we tested would be expected to be 
extensively bound both in vitro and in vivo.  We considered the physico-chemical properties of our 
test and reference substances, and in particular our key comparator, DIM.  Based on this evaluation 
we determined that in vitro and in vivo exposures to free DIM (and the other test substances) are 
likely to be within one order of magnitude of their nominal concentration, although analytical 
determination of free DIM in the assay medium and plasma protein binding would provide further 
confirmation of this.   
7. CONCLUSION 
Historically, reporter gene assays for endocrine modes of action have been used to prioritize 
chemicals for follow-up in subsequent in vivo studies, to assess whether the endocrine activity seen in 
vitro translates to an in vivo adverse effect and to set a point of departure (e.g. a no-observed-adverse-
effect level) for risk assessment.  One of the objectives of this study was to investigate use of 
exposure data at an earlier step in this paradigm to prevent the need to generate animal data on 
chemicals with low activity relative to their associated human exposures.  We found that the use of 
DCRs is a pragmatic approach which allows novel chemical exposures (as described by the bakuchiol 
case study) to be put into context against normal dietary exposure to anti-androgens such as DIM, and 
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against other anti-androgenic chemicals.  The DCR approach may have utility for other modes of 
action where appropriate comparators can be identified. 
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Figure 1 Androgen receptor antagonism results for hydroxyflutamide.  
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Figure 2 Androgen receptor antagonism and specificity control results for genistein, DIM, resveratrol and 
bakuchiol. Each graph represents mean data from at least 3 independent experiments, error bars ±SEM.  No 
model curve shown for bakuchiol at DHT 100×EC50 as chosen model did meet goodness of fit criteria.  
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Figure 3 Comparison of AR CALUX® point of departure (IC50 or  PC50) and measured or predicted serum or 
plasma exposure.  Circles represent IC50 values, triangles represent serum or plasma exposure.  Dietary 
comparator (DIM) in blue, case study ingredient (bakuchiol) with hypothetical exposure scenarios in 
red.  Bakuchiol uses PC50 rather than IC50.   For exposure data, where values for uncertainty (e.g. 95%CI) or 
variability (e.g. percentile exposure) were published these are as described in the supplementary materials. 
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Figure 4 Dietary comparator ratios (DCR). Dietary comparator (DIM) in blue, case study ingredient 
(bakuchiol) with hypothetical exposure scenarios in red.  
 
94x92mm (300 x 300 DPI)  
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/toxsci/advance-article-abstract/doi/10.1093/toxsci/kfy245/5106021 by U
niversity of C
entral Lancashire user on 24 Septem
ber 2018
